Michael Cloutier

Mike Cloutier is an accomplished business leader and consultant with over 39 years in the Life Sciences sector. Over the past 25 years, Mike was General Manager, President and CEO of five major pharmaceutical firms and one Not for Profit organization, the Canadian Diabetes Association (now Diabetes Canada). In 2017, Mike founded a Canadian based global consulting practice, Accelera Canada Ltd. Accelera Canada provides unique and unparalleled “one top support” to US and European based biotech/pharmaceutical companies exploring commercial entry to Canada. www.acceleracanada.com Most recently, Mike co-founded Novescend (Accelera MedTech Canada Inc.) to provide consultation, in-licensing and distribution to US/EU based medical device innovators.


Prior to his role at Accelera Canada, Mike led organizations with interests in the Orphan and Rare disease market segments. As the General Manager and President of PTC Therapeutics Canada and InterMune Canada Inc., he ensured the delivery of tremendous support to patients and caregivers. These companies drove exceptional results in terms of optimal access for patients in need and financial success.

Mike has held positions in Latin America and Europe, serving as Senior Director, Operations, Latin America/Canada and as the Vice-President, Human Resources – Global Marketing for AstraZeneca Inc.
Mike has been responsible for Life Cycle Management in a number of his senior leadership roles. In Canada, as both a senior marketing leader and as the CEO of a number of companies, he has been responsible to develop the strategy and to ensure excellence in the tactical implementation of plans for products in early, mid and late stages of their life cycle. He has engaged in many significant therapeutic classes including Oncology, Neuro-muscular, Cardiology, Gastroenterology, Infectious Disease and Inflammation. Mike has also provided leadership on a global scale in the US, Europe and Latin America.

His leadership in Operations and Global Marketing provided Mike with the opportunity to set clear direction in determining the breadth and depth of product portfolios at Searle and AstraZeneca.
Mike is active on a strategic level sitting and leading a variety of Boards. He chairs the Board of Directors at Arylide Canada, sits on the Boards of OBIO and Alimentiv. He has previously Chaired the Board of Directors at Scientus, Merus Labs International and was a Board Director at Joule , a subsidiary of the Canadian Medical Association. As a result, Mike has an extensive network throughout Canada, the US and International circles.

Mike is a respected, dedicated philanthropist and has served on numerous Boards as a volunteer including the Canadian Stroke Network, Sheridan College Institute of Technology and Advanced Learning and the Canadian Orthopaedic Foundation. Mike is the past Fundraising Chair of the Hazel McCallion Academic Learning Centre at the University of Toronto Mississauga.


Among his many accomplishments, Mike was inducted to the Sheridan College School of Business Marketing Hall of Fame and the Canadian Pharmaceutical Marketing Hall of Fame.



I am energized by this role on the Board as it creates an opportunity for me to contribute my experience, my business acumen and to engage my network with the goal of creating ongoing success for this formidable organization.

Ross Feldman

Dr. Ross Feldman is Medical Director, Cardiac Sciences Program for the Winnipeg Regional Health Authority, in addition he is also Professor of Medicine at the University of Manitoba.

He was just recently the Chair of Medicine at Memorial University of Newfoundland, St. John’s Newfoundland & Labrador, Canada. He is the author of more than 200 original manuscripts, reviews and book chapters. His clinical research program centers on the development of new approaches to the management of hypertension and specifically the development of innovative strategies to improve blood pressure control.

A major focus of his efforts has been in the prevention and control of hypertension in Canada and specifically in the knowledge translation of optimal treatment approaches for hypertension management. Among past leadership positions, Dr. Feldman served as the first Chair of the Steering Committee of the Canadian Hypertension Education Program, the organization that since 1999 has produced, disseminated and implemented annually updated guidelines for management of hypertension. As well, he served as President of the Canadian Hypertension Society. He was also the founding President of Hypertension Canada- leading the process of integrating the efforts of the Canadian Hypertension Society, Canadian Hypertension Education Program and Blood Pressure Canada.

He has received a number of awards and scholarships in recognition of his contributions in research, teaching and for his efforts in the prevention and control of hypertension in Canada. These include the George Morris Piersol Research and Teaching Scholarship from the American College of Physicians, a Career Investigator Award from the Heart and Stroke Foundation of Ontario, the Burroughs-Wellcome Clinical Pharmacology Award and the Senior Investigator Award from the Canadian Society for Clinical Pharmacology as well as the Distinguished Service/Research Award of the Canadian Hypertension Society. He also the recipient of the George Fodor Award from Hypertension Canada for outstanding contributions to the prevention and control of hypertension.

Paul Knill

Paul Knill earned his law degree from Western University, and is a graduate of the Institute of Corporate Directors, Rotman School of Management.

Paul served as Managing Partner at the Canadian Law Firm, Siskinds LLP, during a period of significant expansion and change. His leadership encouraged innovative gathering and sharing of intellectual capital among business unit members. Paul went on to serve as an adjunct professor at Western University law school, and he currently contributes his corporate governance expertise by serving on the boards of a diverse number of Corporations.